JHL has several developed several biosimilars that are either currently in or expected to be in clinical trial in 2018, including:
JHL has submitted the relevant applications to regulators to voluntarily terminate trading of JHL shares on the Emerging Stock Market of Taipei Exchange (TPEx).
JHL was granted the award for groundbreaking use of innovative design and technology at its facility in Wuhan, China.
JHL is honored to receive recognition for its work and attributes its success to the fantastic team the company has built and to its longstanding partnership with GE.
Under the partnership, ASLAN will work with JHL to perform process development and manufacturing of ASLAN004, a fully human monoclonal antibody that blocks the signalling of the IL-4 and IL-13 receptors.
Mark McHale, Chief Operating Officer, ASLAN Pharmaceuticals, said: ASLAN is pleased to be working with a high quality partner like JHL, whose capabilities in process development and manufacturing will enable us to accelerate the development of our unique and proprietary biologics pipeline.
JHL exists to make world-class medicines affordable to all, with a focus on broadening access to life-saving therapies in Asia.
JHL will use the KUBio manufacturing solution delivered by GE Healthcare to manufacture biosimilars and monoclonal antibodies (mAbs) for latestage clinical trials and commercial supply.
JHL and GE Healthcare partnered to complete the construction of the facility in just 18 months using GEs KUBio manufacturing solution.
Chief Executive Officer Racho Jordanov said, JHL
is the first company from Greater China to receive European approval to conduct biosimilar clinical trial, which speaks to the quality of our team and commitment of our people.